Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PAVM |
---|---|---|
09:32 ET | 1210 | 1.06 |
09:42 ET | 200 | 1.05 |
09:46 ET | 147 | 1.0428 |
09:50 ET | 1086 | 1.0599 |
09:51 ET | 226 | 1.0548 |
09:53 ET | 100 | 1.045 |
10:08 ET | 9240 | 1.06 |
10:13 ET | 1033 | 1.04 |
10:18 ET | 125 | 1.0735 |
10:44 ET | 100 | 1.08 |
10:49 ET | 463 | 1.0799 |
10:56 ET | 550 | 1.06 |
11:18 ET | 600 | 1.06 |
11:20 ET | 300 | 1.06 |
11:21 ET | 100 | 1.06 |
11:27 ET | 11387 | 1.08 |
11:36 ET | 100 | 1.08 |
11:39 ET | 403 | 1.09 |
11:43 ET | 1000 | 1.0718 |
11:56 ET | 337 | 1.072 |
12:15 ET | 100 | 1.0832 |
12:24 ET | 200 | 1.097 |
12:35 ET | 284 | 1.09 |
12:39 ET | 1600 | 1.0883 |
12:50 ET | 200 | 1.0877 |
01:15 ET | 900 | 1.079 |
01:20 ET | 116 | 1.08 |
01:26 ET | 600 | 1.0733 |
01:38 ET | 12060 | 1.11 |
01:47 ET | 200 | 1.1178 |
01:54 ET | 604 | 1.11 |
02:03 ET | 722 | 1.1077 |
02:50 ET | 691 | 1.09 |
03:10 ET | 115 | 1.12 |
03:24 ET | 566 | 1.1 |
03:30 ET | 500 | 1.12 |
03:32 ET | 1891 | 1.12 |
03:33 ET | 239 | 1.101 |
03:44 ET | 816 | 1.11 |
03:46 ET | 2329 | 1.11 |
03:51 ET | 1055 | 1.115 |
04:00 ET | 200 | 1.11 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
PAVmed Inc | 11.6M | -0.1x | --- |
ADM Tronics Unlimited Inc | 5.1M | -10.7x | --- |
BioElectronics Corp | 6.2M | -12.5x | --- |
Optimus Healthcare Services Inc | 5.9M | -0.7x | --- |
Longport Inc | 2.3K | 0.0x | --- |
Aksys Ltd | 30.0 | 0.0x | --- |
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $11.6M |
---|---|
Revenue (TTM) | $3.8M |
Shares Outstanding | 10.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.71 |
EPS | $-8.17 |
Book Value | $-6.28 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 3.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,704.81% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.